Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes
- 1.3k Downloads
The aim of this study was to compare glycaemic control and maternal–fetal outcomes in women with type 1 diabetes managed on insulin pumps compared with multiple daily injections of insulin (MDI).
In a retrospective study, glycaemic control and outcomes of 387 consecutive pregnancies in women with type 1 diabetes who attended specialised clinics at three centres 2006–2010 were assessed.
Women using insulin pumps (129/387) were older and had a longer duration of diabetes, more retinopathy, smoked less in pregnancy, and had more preconception care (p < 0.01 for each). Among 113 pregnancies >20 weeks’ gestation in women on insulin pumps and 218 in women on MDI, there was a significant difference in HbA1c in the first trimester (mean HbA1c 6.90 ± 0.71% (52 ± 7.8 mmol/mol) vs 7.60 ± 1.38% (60 ± 15.1 mmol/mol), p < 0.001), which persisted until the third trimester (mean HbA1c 6.49 ± 0.52% (47 ± 5.7 mmol/mol) vs 6.81 ± 0.85% (51 ± 9.3 mmol/mol), p = 0.002). Rates of diabetic ketoacidosis were similar in women on insulin pumps vs MDI (1.8% vs 3.0%, p = 0.72). Despite lower HbA1c, women on insulin pumps did not have an increased incidence of severe hypoglycaemia (8.0% vs 7.6%, p = 0.90) or more weight gain (16.3 ± 8.7 vs 15.2 ± 6.2 kg, p = 0.18). More large-for-gestational-age infants in the pump group (55.0% vs 39.2%, p = 0.007) may have resulted from confounding by parity.
In this large multicentre study, women using insulin pumps in pregnancy had lower HbA1c without increased risk of severe hypoglycaemia or diabetic ketoacidosis but no improvement in other pregnancy outcomes. This information can help inform care providers and patients about the glycaemic effectiveness and safety of insulin pumps in pregnancy.
KeywordsContinuous subcutaneous insulin infusion Diabetes Insulin pump Multiple daily injections Pregnancy Type 1 diabetes
Multiple daily injections of insulin
We are grateful to the Data Integration Measurement and Reporting department, the Alberta Perinatal Health Program, and Research Excellence and Support Team of Alberta Health Services (Alberta, Canada) for their contributions.
Our study was supported by funding from the Stewart Diabetes Fund (Alberta, Canada) and the British Columbia Endocrine Research Foundation (British Columbia, Canada).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
MMK-K, JMK and LED conceived and designed the study. SB, AKL and KIL also contributed to the study design. MMK-K collected the data, obtained funding and wrote the manuscript. JMK, LED and JAK facilitated data acquisition at their respective sites. SB contributed to data collection. QMD performed the statistical analysis. LED, JMK, JAK, SB, KIL, QMD and AKL critically reviewed and provided comments on the manuscript. All authors approved the final version.
- 5.Bruttomesso D, Bonomo M, Costa S et al (2011) Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab 37:426–431PubMedCrossRefGoogle Scholar
- 7.Chen R, Ben-Haroush A, Weissman-Brenner A, Melamed N, Hod M, Yogev Y (2007) Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 197:404.e1–404.e5Google Scholar
- 13.Statistics Canada (2006) 2006 Census Dictionary. Statistics Canada, Ottawa, ON, CanadaGoogle Scholar
- 16.Public Health Agency of Canada (2008) Canadian Perinatal Health Report, 2008 Edition. Public Health Agency of Canada, Ottawa, ON, CanadaGoogle Scholar
- 17.European Surveillance of Congenital Anomalies (2005) EUROCAT Guide 1.3 and reference documents. EUROCAT Central Registry, Newtownabbey, Northern Ireland, UKGoogle Scholar
- 35.Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J (2010) Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev, Issue 1, Art no.: CD005103Google Scholar